Brief: Irlab’S Phase IIb Study With Pirepemat Passes Dsmb Safety Review

IRLAB Therapeutics AB

17/07/2023 06:11

July 17 (Reuters) - IRLAB Therapeutics AB  IRLABa.ST :
    * IRLAB’S PHASE IIB STUDY WITH PIREPEMAT PASSES DSMB SAFETY
REVIEW
WITH UNANIMOUS RECOMMENDATION TO CONTINUE THE ONGOING PHASE IIB
STUDY

Source text for Eikon:  ID:nMFN41K0gT 
Further company coverage:  IRLABa.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))